Home » Stocks » Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. (VNDA)

Stock Price: $12.00 USD 0.50 (4.35%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 654.61M
Revenue (ttm) 240.62M
Net Income (ttm) 113.84M
Shares Out 54.55M
EPS (ttm) 2.08
PE Ratio 5.77
Forward PE 30.30
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $12.00
Previous Close $11.50
Change ($) 0.50
Change (%) 4.35%
Day's Open 11.55
Day's Range 11.13 - 12.07
Day's Volume 560,732
52-Week Range 7.12 - 17.85

More Stats

Market Cap 654.61M
Enterprise Value 326.48M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 54.55M
Float 40.37M
EPS (basic) 2.12
EPS (diluted) 2.08
FCF / Share 0.70
Dividend n/a
Dividend Yield n/a
Earnings Yield 17.33%
FCF Yield 5.80%
Payout Ratio n/a
Shares Short 6.23M
Short Ratio 9.08
Short % of Float 13.78%
Beta 0.47
PE Ratio 5.77
Forward PE 30.30
P/FCF Ratio 17.25
PS Ratio 2.72
PB Ratio 1.38
Revenue 240.62M
Operating Income 24.05M
Net Income 113.84M
Free Cash Flow 37.94M
Net Cash 328.13M
Net Cash / Share 6.02
Gross Margin 84.24%
Operating Margin 9.99%
Profit Margin 47.30%
FCF Margin 15.77%
ROA 3.42%
ROE 31.26%
ROIC 8.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$18.33*
(52.75% upside)
Low
14.0
Current: $12.00
High
25.0
Target: 18.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue22719316514611050.1633.8832.7331.2735.71
Revenue Growth17.64%16.98%13.06%32.83%119.16%48.05%3.52%4.66%-12.43%-
Gross Profit20317314712186.4648.5733.8832.6031.2732.82
Operating Income22.8121.74-16.90-18.57-40.1920.06-21.20-29.18-10.718.84
Net Income11625.21-15.57-18.01-39.8720.19-21.06-28.62-9.807.19
Shares Outstanding53.1450.8644.7443.4542.2534.7730.3528.2328.1127.92
Earnings Per Share2.110.48-0.35-0.41-0.940.55-0.69-1.01-0.350.25
EPS Growth339.58%---------
Operating Cash Flow45.9529.99-1.98-8.1012.45-81.55-39.59-44.92-28.41-10.90
Capital Expenditures-1.02-25.37-1.66-1.41-2.53-0.77-0.18-2.02-0.280.07
Free Cash Flow44.934.62-3.65-9.519.92-82.32-39.77-46.93-28.69-10.83
Cash & Equivalents312257143141143130131121149198
Total Debt12.46---------
Net Cash / Debt300257143141143130131121149198
Assets484332205210213172143135183213
Liabilities72.8056.7174.0479.0480.0210.8999.23126149175
Book Value41127513113113316144.129.9133.4737.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vanda Pharmaceuticals Inc.
Country United States
Employees 284
CEO Mihael Hristos Polymeropoulos

Stock Information

Ticker Symbol VNDA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VNDA
IPO Date April 12, 2006

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.